Moreover, in patients with biopsy-proven NAFLD, PNPLA3 G/-, TM6SF2 T/- and HSD17B13 TA/- carriage were found to be associated with the severity of NAFLD, and combining PNPLA3 (rs738409, p = 0.0076), HSD17B13 (rs72613567), and TM6SF2(rs10401969, p = 0.0076), MBOAT7 (rs641738) with clinical data further increased the accuracy for predicting the severity of NASH and/or advanced fibrosis (Ioannou, 2021; Paternostro et al., 2021). Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.